- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02682069
Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X(TM) Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
Study Overview
Detailed Description
MolecuLight Inc. (Toronto, Canada) has recently introduced to the Canadian market an innovative imaging device, the MolecuLight i:X™ Imaging Device, that offers real-time detection of important biological and molecular information of a chronic wound, and could have significant impact on improving conventional wound care and management. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the chronic wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present. Though the MolecuLight i:X Imaging Device has been shown to be effective in controlled settings, this study is deploying the device in a larger population and evaluating the ability of the MolecuLight i:X device to positively predict the presence of bacteria in chronic wounds.
The overall objective of this work is to evaluate the MolecuLight i:X Imaging Device in screening of chronic wounds for the presence of bacteria. The device is intended to guide the clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
All imaging will be performed with the MolecuLight i:X Imaging Device at an appropriate distance from the wound of interest (8 - 12 cm), which is indicated by the range finder LED. Illumination is provided by two violet (405 nm) LEDs that produce a bright, but clinically safe, uniform illumination. Fluorescence imaging is performed on the camera in real-time while the device is in fluorescence mode and the room lights are turned off. If room ambient light cannot be eliminated to an acceptable level (indicated by the ambient light sensor), the MolecuLight drape must be used to achieve a dark environment. A standard measurement sticker will be placed adjacent to the wound within the field of view to act as a reference for size.
All microbiological analysis will be performed as per standard practice at each local clinic. Tissue samples will be analyzed for culture and sensitivity, yielding the species of bacteria present in the sample (if any), the susceptibility to various antibiotics and a measure of the bacterial load.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients presenting with chronic wound of the lower limb (e.g. diabetic foot ulcer, venous leg ulcer, other acceptable aetiology)
- 18 years or older
Exclusion Criteria:
- Treatment with an investigational drug within 1 month before study enrolment
- Use of systemic (oral or intravenous) antibiotics
- Inability to consent
- Any contra-indication to routine wound care and/or monitoring
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All patients
There is one arm to this study and all patients will undergo the same procedures.
The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations.
Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
|
The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels.
The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection.
The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination.
This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive Predictive Value (PPV) - Ability of Fluorescence Imaging With the MolecuLight i:X to Predict Presence of Bacterial Loads of 104 CFU/g and Greater
Time Frame: Baseline
|
PPV reflects the probability that a region of red fluorescence within or around a wound will contain bacteria.
Meaning the number cases where qPCR analysis of wound tissue biopsies from red fluorescent region showed to have pathogen load ≥ 104 CFU/g divided by the total number of cases where red florescence was observed in the wound multiplied by 100,
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ron Wolcott, MD, Southwest Regional Wound Care Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds
-
Centre Hospitalier Universitaire de NīmesCompleted
-
3MWithdrawn
-
University of WashingtonU.S. Department of Justice; Arnold Ventures; City of SeattleCompleted
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Ohio State UniversityCompleted
-
University of PittsburghThe Pittsburgh Foundation; Hillman Foundation; RK Mellon FoundationCompletedSkin Injury Due to Violence | Gunshot Wound, ContactUnited States
-
Smith & Nephew, Inc.Not yet recruitingChronic Wounds | Acute WoundsCanada
-
SerenaGroup, Inc.MDM Wound Ventures, LLCCompletedChronic Wounds | Acute WoundsUnited States
-
SerenaGroup, Inc.Anacapa Technologies IncCompleted
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
Clinical Trials on MolecuLight i:X Imaging Device
-
MolecuLight Inc.RecruitingNon Healing Diabetic Foot UlcerUnited States
-
MolecuLight Inc.SerenaGroup, Inc.Unknown
-
Calver PangUnknownWound Infection | WoundUnited Kingdom
-
MolecuLight Inc.UnknownSkin Graft (Allograft)(Autograft) FailureUnited Kingdom
-
The Leeds Teaching Hospitals NHS TrustUnknown
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR)Not yet recruitingDiabetic Foot Ulcer
-
Croydon Health Services NHS TrustCompletedAnal Sphincter Injury | Obstetric Trauma | Perineal Infection | Perineum; InjuryUnited Kingdom
-
Wound Care Plus, LLCCompletedNon-Healing Ulcer of Skin | Autofluorescence ImagingUnited States
-
NYU Langone HealthNational Eye Institute (NEI)CompletedGlaucoma | Eye Diseases | Age-Related Macular Degeneration | Diabetic Retinopathy | Central Serous Chorioretinopathy | Glaucoma, SuspectUnited States